ÏÂÃ泭×ÔFDA Îļþ¡£
»ÔÈð
Available safety data from all participants enrolled through the November 14, 2020, data cut-off ( N=43,252, which includes late enrollment of additional adolescent and adultparticipants), was consistent with the safety profile for the approximately 38,000 ¡¡
µÚ39ҳ±íÏÂעÃ÷£º×îºóһ¸ö־ԸÕß10ÔÂ9ÈÕעÉ䡣
Participants >16 years of age enrolled by October 9, 2020¡£
https://www.fda.gov/media/144416/download
ÔڴóѡǰÊÇΨ±»Åúµġ£
Moderna COVID-19 Vaccine
https://www.fda.gov/media/144434/download
Efficacy data from the final scheduled analysis of the primary efficacy endpoint (data cutoff of November 21, 2020, with a median follow-up of >2 months post-dose 2) demonstrated a VE of 94.1% (95% CI 89.3%, 96.8%), with 11 COVID-1
»ÔÈð
Available safety data from all participants enrolled through the November 14, 2020, data cut-off ( N=43,252, which includes late enrollment of additional adolescent and adultparticipants), was consistent with the safety profile for the approximately 38,000 ¡¡
µÚ39ҳ±íÏÂעÃ÷£º×îºóһ¸ö־ԸÕß10ÔÂ9ÈÕעÉ䡣
Participants >16 years of age enrolled by October 9, 2020¡£
https://www.fda.gov/media/144416/download
ÔڴóѡǰÊÇΨ±»Åúµġ£
Moderna COVID-19 Vaccine
https://www.fda.gov/media/144434/download
Efficacy data from the final scheduled analysis of the primary efficacy endpoint (data cutoff of November 21, 2020, with a median follow-up of >2 months post-dose 2) demonstrated a VE of 94.1% (95% CI 89.3%, 96.8%), with 11 COVID-1
���༭ʱ��: 2021-05-17 18:43:31

